Table 3 Selected ongoing CAR-T trials targeting CD123, CD22, CD33, CD38, and CD138
From: Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
NCT number | Phase | n | Conditions | Interventions | Sponsor/location |
|---|---|---|---|---|---|
NCT03672851 | I | 30 | RR AML | CD123 CAR-T | China |
NCT03631576 | II/II | 20 | RR AML | CD123/CLL1 CAR-T | China |
NCT02937103 | I/II | 45 | RR CD123+ myeloid malignancies | CD123-CAR-T | China |
NCT03398967 | I/II | 80 | RR B cell leukemia and lymphoma | Dual specificity CD19 and CD20 or CD22 CAR-T | China |
NCT03330691 | I | 33 | CD19+, CD22+ RR leukemia and lymphoma | Dual specificity CD19-HER2t CAR-T and CD22 EGFRt CAR-T | Seattle Children’s Hospital, USA |
NCT03620058 | I | 18 | RR B-ALL | CART22-65s ± huCART19 | UPENN |
NCT02650414 | I | 15 | RR B-ALL | CD22 CART | UPENN, CHOP |
NCT03098355 | I | 30 | RR B-ALL or NHL | 4SCAR19/22 ± interleukin-2 | China |
NCT03126864 | I | 39 | RR CD33+ AML | CD33-CAR-T | MDACC, USA |
NCT02958397 | I/II | 45 | RR CD33+ myeloid malignancies | CD33-CAR-T | China |
NCT03464916 | I | 72 | RR MM | CAR2 CD38 A2 CAR-T | USA |
NCT03754764 | I/II | 80 | RR B-ALL | CD38 CAR-T after CD-19 CAR-T relapse | China |
NCT03672318 | I | 33 | RR MM | ATLCAR.CD138 CAR-T | USA |
NCT03196414 | I/II | 10 | RR MM | CART-138/BCMA CAR-T | USA |
NCT03778346 | I/II | 30 | RR MM | Fourth-generation Integrin ß7/BCMA/CS1/CD38/CD138 CAR-T or 10 different combinations | China |
NCT03767751 | I/II | 80 | RR MM | Dual CD38/BCMA CAR-T | China |
NCT03222674 | I/II | 10 | RR AML | Muc1/CLL1/CD33/CD38/CD56/CD123 CAR-T | China |